The phase III LAURA study assessed the efficacy and safety of osimertinib in patients with unresectable stage III EGFR-mutated non–small cell lung cancer (NSCLC) without disease progression after definitive chemoradiotherapy. Results were presented by Ramalingam et al at the 2024 ASCO Annual Meeting (Abstract LBA4).
